Key result
ADHF with HFmrEF is linked to ~11% higher risk of CV death and rehospitalization versus HFpEF.
Why the study?
Little research has investigated ischemic outcomes related to left ventricular ejection fraction in acute decompensated heart failure.
Does the HFmrEF phenotype alter the risk of ischemic outcomes and mortality compared to HFrEF and HFpEF in patients with acute decompensated heart failure?
Population
12,852 ADHF patients
Comparison
HFmrEF vs HFrEF and HFpEF
Design
Multi-institutional retrospective cohort study
Authors
Loading...
HFmrEF signals elevated CV death and rehospitalization risk in acute decompensated HF; leaves open whether phenotype-specific interventions improve outcomes.
Cohort (n=12,852)
Yes
Does the HFmrEF phenotype alter the risk of ischemic outcomes and mortality compared to HFrEF and HFpEF in patients with acute decompensated heart failure?
Effect estimate: AHR 1.11 (95% CI 1.04-1.18)
Absolute Event Rate: 56.4% vs 51.2%
p-value: p=0.002
In patients with acute decompensated heart failure, the HFmrEF phenotype is associated with a distinct comorbidity profile and a higher crude rate of acute myocardial infarction compared to HFrEF and HFpEF.
Lin et al. (2023) conducted a cohort in Acute decompensated heart failure (n=12,852). Heart failure with mildly reduced ejection fraction (HFmrEF) vs. Heart failure with preserved ejection fraction (HFpEF) was evaluated on Cardiovascular death and heart failure rehospitalization (AHR 1.11, 95% CI 1.04-1.18, p=0.002). Patients with acute decompensated heart failure and mildly reduced ejection fraction had a significantly higher risk of cardiovascular death and heart failure rehospitalization compared to those with preserved ejection fraction (AHR 1.11).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: